BIOMARIN PHARMACEUTICAL INC Finance Lease, Liability, to be Paid, Year Two
BIOMARIN PHARMACEUTICAL INC (BMRN) had Finance Lease, Liability, to be Paid, Year Two of $222.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2026-02-26
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Two $222.00K.
- 2024-12-31: Finance Lease, Liability, to be Paid, Year Two $323.00K.
- 2023-12-31: Finance Lease, Liability, to be Paid, Year Two $75.00K.
- 2022-12-31: Finance Lease, Liability, to be Paid, Year Two $123.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2025-12-31 | $222.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $323.00K 10-K · filed 2025-02-24 |
| 2023-12-31 | $75.00K 10-K · filed 2024-02-26 |
| 2022-12-31 | $123.00K 10-K · filed 2023-02-27 |
| 2021-12-31 | $1.87M 10-K · filed 2022-02-25 |
| 2020-12-31 | $2.38M 10-K · filed 2021-02-26 |
| 2020-09-30 | $2.38M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $2.33M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $3.07M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $3.09M 10-K · filed 2020-02-27 |
| 2019-09-30 | $3.46M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $3.47M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $3.46M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |